Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TNT-OES-2: Total Neoadjuvant Therapy for Node-Positive Esophageal and EGJ Adenocarcinoma
2025-521158-40-00Phase 2Authorised
- Sponsor
- Erasmus MC
- Start
- Aug 2025
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of folinic acid, fluorouracil, oxaliplatin, docetaxel, paclitaxel and 1 more in esophageal adenocarcinoma (EAC) and gastroesophageal junction adenocarcinoma (2 arms), sponsored by Erasmus MC. Primary endpoint: Progression-free survival. Planned start Aug 2025; status: authorised.
02
Drugs
folinic acidfluorouraciloxaliplatindocetaxelpaclitaxel
03
Conditions
esophageal adenocarcinoma (EAC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on 2025-521158-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521158-40-00.